These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC. Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648 [TBL] [Abstract][Full Text] [Related]
63. Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma. Liang S; Ji L; Yu Z; Cheng Y; Gao R; Yan W; Zhang F Hereditas; 2024 Feb; 161(1):10. PubMed ID: 38414024 [TBL] [Abstract][Full Text] [Related]
64. Identification and verification of aging-related lncRNAs for prognosis prediction and immune microenvironment in patients with head and neck squamous carcinoma. Gao Q; Shi Y; Sun Y; Zhou S; Liu Z; Sun X; DI X Oncol Res; 2023; 31(1):35-61. PubMed ID: 37303739 [TBL] [Abstract][Full Text] [Related]
65. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma. Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H Front Immunol; 2022; 13():933241. PubMed ID: 36211378 [TBL] [Abstract][Full Text] [Related]
66. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer. Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791 [No Abstract] [Full Text] [Related]
67. SLA2 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment. Wu Z; You C; Zhu Z; Wu W; Cao J; Xie Q; Deng C; Huang X; Hu S Eur Arch Otorhinolaryngol; 2024 Jan; 281(1):427-440. PubMed ID: 37688682 [TBL] [Abstract][Full Text] [Related]
68. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment. Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023 [TBL] [Abstract][Full Text] [Related]
69. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer. Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X Front Oncol; 2023; 13():1083956. PubMed ID: 37384293 [TBL] [Abstract][Full Text] [Related]
70. Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma. Gong H; Liu Z; Yuan C; Luo Y; Chen Y; Zhang J; Cui Y; Zeng B; Liu J; Li H; Deng Z Comput Biol Med; 2024 Mar; 171():108198. PubMed ID: 38417385 [TBL] [Abstract][Full Text] [Related]
71. A novel metabolic-related gene signature for predicting clinical prognosis and immune microenvironment in head and neck squamous cell carcinoma. Cao Y; Dai Z; Xie G; Liu G; Guo L; Zhang J Exp Cell Res; 2023 Jul; 428(2):113628. PubMed ID: 37149080 [TBL] [Abstract][Full Text] [Related]
72. Predicting the Immune Microenvironment and Prognosis with a NETosis-Related lncRNA Signature in Head and Neck Squamous Cell Carcinoma. He X; Xiao Y; Liu S; Deng R; Li Z; Zhu X Biomed Res Int; 2022; 2022():3191474. PubMed ID: 36147630 [TBL] [Abstract][Full Text] [Related]
73. Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer. Li N; Yu K; Huang D; Li S; Zeng D; Li J; Fan L Biol Trace Elem Res; 2024 Apr; 202(4):1428-1445. PubMed ID: 37528285 [TBL] [Abstract][Full Text] [Related]
74. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma. Huang Y; Gong P; Su L; Zhang M Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210 [TBL] [Abstract][Full Text] [Related]
75. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L Front Genet; 2023; 14():1056000. PubMed ID: 36845390 [No Abstract] [Full Text] [Related]
76. Investigating diagnostic potential of long non-coding RNAs in head and neck squamous cell carcinoma using TCGA database and clinical specimens. Lan T; Yan Y; Zheng D; Ding L Sci Rep; 2024 Mar; 14(1):7500. PubMed ID: 38553620 [TBL] [Abstract][Full Text] [Related]
77. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Pan Y; Zhang Q; Zhang H; Kong F Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225 [TBL] [Abstract][Full Text] [Related]
78. An ion-channel-gene-based prediction model for head and neck squamous cell carcinoma: Prognostic assessment and treatment guidance. Han Y; Shi Y; Chen B; Wang J; Liu Y; Sheng S; Fu Z; Shen C; Wang X; Yin S; Li H Front Immunol; 2022; 13():961695. PubMed ID: 36389709 [TBL] [Abstract][Full Text] [Related]
79. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma. Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612 [TBL] [Abstract][Full Text] [Related]
80. The prognostic value and immune landscape of a cuproptosis-related lncRNA signature in head and neck squamous cell carcinoma. Li YJ; Li HY; Zhang Q; Wei SL Front Genet; 2022; 13():942785. PubMed ID: 35942287 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]